VEU11 VEU21, VEU02, VEU01, V015T, V015, Reach Power Cadence VAX Belts Belts x2 Vacuum Parts & Accessories


  1. Home
  2. VEU11 VEU21, VEU02, VEU01, V015T, V015, Reach Power Cadence VAX Belts Belts x2
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
VAX Cadence Power Reach V015, V015T, VEU01, VEU02, VEU21, VEU11 Belts x2 Belts
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Type: Belt
Brand:

Vax

For Vacuum Cleaner Brand: Vax
MPN:

Does Not Apply

To Fit Models: V015, V015T, VEU01, VEU02, VEU21, VEU11, V044
EAN:

Does not apply

published on tue nov 09 2021

VEU11 VEU21, VEU02, VEU01, V015T, V015, Reach Power Cadence VAX Belts Belts x2 Vacuum Parts & Accessories

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

VEU11 VEU21, VEU02, VEU01, V015T, V015, Reach Power Cadence VAX Belts Belts x2 Vacuum Parts & Accessories

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS